Literature DB >> 21850051

AAV vectors transduce hepatocytes in vivo as efficiently in cirrhotic as in healthy rat livers.

L Sobrevals1, M Enguita, C Rodriguez, J Gonzalez-Rojas, P Alzaguren, N Razquin, J Prieto, P Fortes.   

Abstract

In liver cirrhosis, abnormal liver architecture impairs efficient transduction of hepatocytes with large viral vectors such as adenoviruses. Here we evaluated the ability of adeno-associated virus (AAV) vectors, small viral vectors, to transduce normal and cirrhotic rat livers. Using AAV serotype-1 (AAV1) encoding luciferase (AAV1Luc) we analyzed luciferase expression with a CCD camera. AAV1Luc was injected through the hepatic artery (intra-arterial (IA)), the portal vein (intra-portal (IP)), directly into the liver (intra-hepatic (IH)) or infused into the biliary tree (intra-biliar). We found that AAV1Luc allows long-term and constant luciferase expression in rat livers. Interestingly, IP administration leads to higher expression levels in healthy than in cirrhotic livers, whereas the opposite occurs when using IA injection. IH administration leads to similar transgene expression in cirrhotic and healthy rats, whereas intra-biliar infusion is the least effective route. After 70% partial hepatectomy, luciferase expression decreased in the regenerating liver, suggesting lack of efficient integration of AAV1 DNA into the host genome. AAV1Luc transduced mainly the liver but also the testes and spleen. Within the liver, transgene expression was found mainly in hepatocytes. Using a liver-specific promoter, transgene expression was detected in hepatocytes but not in other organs. Our results indicate that AAVs are convenient vectors for the treatment of liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21850051     DOI: 10.1038/gt.2011.119

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  22 in total

1.  CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation.

Authors:  Aftab Ullah; Kaikai Wang; Pengkai Wu; David Oupicky; Minjie Sun
Journal:  Int J Nanomedicine       Date:  2019-04-26

Review 2.  New gene therapy strategies for hepatic fibrosis.

Authors:  Adriana M Salazar-Montes; Luis D Hernández-Ortega; Martha S Lucano-Landeros; Juan Armendariz-Borunda
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

Review 3.  Regulation of hepatocyte identity and quiescence.

Authors:  Carmen Berasain; Matías A Avila
Journal:  Cell Mol Life Sci       Date:  2015-06-19       Impact factor: 9.261

4.  Adenoviral gene therapy in hepatocellular carcinoma: a review.

Authors:  Iván Lyra-González; Laura Esther Flores-Fong; Ignacio González-García; David Medina-Preciado; Juan Armendáriz-Borunda
Journal:  Hepatol Int       Date:  2012-04-25       Impact factor: 6.047

5.  Human Hepatocyte Transduction with Adeno-Associated Virus Vector.

Authors:  Zhenwei Song; Wenwei Shao; Liujiang Song; Xieolei Pei; Chengwen Li
Journal:  Methods Mol Biol       Date:  2022

Review 6.  Emerging therapeutic potential of adeno-associated virus-mediated gene therapy in liver fibrosis.

Authors:  Fang-Tian Bu; Peng-Cheng Jia; Yan Zhu; Ya-Ru Yang; Hong-Wu Meng; Yi-Hui Bi; Cheng Huang; Jun Li
Journal:  Mol Ther Methods Clin Dev       Date:  2022-06-22       Impact factor: 5.849

7.  Monitoring Endoplasmic Reticulum Calcium Homeostasis Using a Gaussia Luciferase SERCaMP.

Authors:  Mark J Henderson; Emily S Wires; Kathleen A Trychta; Xiaokang Yan; Brandon K Harvey
Journal:  J Vis Exp       Date:  2015-09-06       Impact factor: 1.355

8.  Long noncoding RNA EGOT negatively affects the antiviral response and favors HCV replication.

Authors:  Elena Carnero; Marina Barriocanal; Celia Prior; Juan Pablo Unfried; Victor Segura; Elizabeth Guruceaga; Mónica Enguita; Cristian Smerdou; Pablo Gastaminza; Puri Fortes
Journal:  EMBO Rep       Date:  2016-06-09       Impact factor: 8.807

9.  MicroRNA 122, Regulated by GRLH2, Protects Livers of Mice and Patients From Ethanol-Induced Liver Disease.

Authors:  Abhishek Satishchandran; Aditya Ambade; Sitara Rao; Ying-Chao Hsueh; Arvin Iracheta-Vellve; David Tornai; Patrick Lowe; Benedek Gyongyosi; Jia Li; Donna Catalano; Li Zhong; Karen Kodys; Jun Xie; Shashi Bala; Guangping Gao; Gyongyi Szabo
Journal:  Gastroenterology       Date:  2017-10-04       Impact factor: 22.682

10.  AAV-mediated liver-specific MPV17 expression restores mtDNA levels and prevents diet-induced liver failure.

Authors:  Emanuela Bottani; Carla Giordano; Gabriele Civiletto; Ivano Di Meo; Alberto Auricchio; Emilio Ciusani; Silvia Marchet; Costanza Lamperti; Giulia d'Amati; Carlo Viscomi; Massimo Zeviani
Journal:  Mol Ther       Date:  2013-07-03       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.